{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-014610","form_type":"8-K","ticker":"DMAC","cik":"0001401040","company_name":"DiaMedica Therapeutics Inc.","filed_at":"2023-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.704270+00:00","generated_at":"2026-06-15T00:51:30.161541+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"DiaMedica files clinical hold response; Q1 cash $28.7M; Phase 1C confirms DM199 dose safety","bullets":["Company will file complete clinical hold response to FDA this week for ReMEDy2 AIS trial; in-use study supports dose revision to 0.5 µg/kg IV.","Phase 1C SAD study in healthy volunteers affirms revised DM199 IV dose is well-tolerated and achieves therapeutic blood levels.","Cash, cash equivalents and investments $28.7M as of March 31, 2023; working capital $26.9M; cash runway into Q4 2024.","R&D expenses $3.6M in Q1 2023, up 80% YoY, driven by clinical hold studies and team expansion; G&A $1.9M, up 19%.","Post-quarter $0.75M private investment from newly appointed Chief Business Officer; net cash used in ops $5.1M in Q1."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-014610","json":"https://secwatch.observer/filing/0001437749-23-014610.json","markdown":"https://secwatch.observer/filing/0001437749-23-014610.md","text":"https://secwatch.observer/filing/0001437749-23-014610.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1401040/000143774923014610/0001437749-23-014610-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1401040/000143774923014610/dmtp20230512_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T00:51:30.161541+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ddc64ac06d99f126278730c21ddb3b0e9437da5a","claim":"DiaMedica Therapeutics Inc. reported financial results for the quarter ended March 31, 2023.","evidence_excerpt":"On May 15, 2023, DiaMedica Therapeutics Inc. (the “Company”) announced its consolidated financial results for the quarter ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1401040/000143774923014610/0001437749-23-014610-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}